| 51 |
31289524 | Radiosensitization effects of curcumin plus cisplatin on non-small cell lung cancer A549 cells. | 2019 Jul |
1 |
| 52 |
31319622 | Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer. | 2019 Jul 17 |
2 |
| 53 |
31360122 | p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling. | 2019 |
7 |
| 54 |
31387179 | Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer. | 2019 Sep |
2 |
| 55 |
31545462 | Lung carcinoma therapy using epidermal growth factor receptor‑targeted lipid polymeric nanoparticles co‑loaded with cisplatin and doxorubicin. | 2019 Nov |
2 |
| 56 |
31553438 | Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. | 2019 Dec 1 |
1 |
| 57 |
31559456 | Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens. | 2019 Dec |
3 |
| 58 |
29101518 | Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations. | 2018 Aug |
1 |
| 59 |
29174310 | Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. | 2018 Jan |
1 |
| 60 |
29328423 | Cetuximab enhances cisplatin-induced endoplasmic reticulum stress-associated apoptosis in laryngeal squamous cell carcinoma cells by inhibiting expression of TXNDC5. | 2018 Mar |
2 |
| 61 |
29344640 | Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR. | 2018 Mar |
4 |
| 62 |
29434871 | Mechanisms for DNA-damaging agent-induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways. | 2018 Feb |
1 |
| 63 |
29551903 | Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells. | 2018 |
1 |
| 64 |
29644460 | Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer. | 2018 Jun |
3 |
| 65 |
29662625 | ADAM17 inhibition enhances platinum efficiency in ovarian cancer. | 2018 Mar 23 |
1 |
| 66 |
29805654 | Cisplatin-induced non-canonical endocytosis of EGFR via p38 phosphorylation of the C-terminal region containing Ser-1015 in non-small cell lung cancer cells. | 2018 Jun |
4 |
| 67 |
29982103 | Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells. | 2018 Aug |
7 |
| 68 |
30021363 | Yes-associated protein enhances proliferation and attenuates sensitivity to cisplatin in human gastric cancer cells. | 2018 Sep |
1 |
| 69 |
30093972 | Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer. | 2018 Jul 17 |
2 |
| 70 |
30320337 | Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1. | 2018 Dec |
3 |
| 71 |
30347860 | Modulation of Hypoxia-Induced Chemoresistance to Polymeric Micellar Cisplatin: The Effect of Ligand Modification of Micellar Carrier Versus Inhibition of the Mediators of Drug Resistance. | 2018 Oct 21 |
3 |
| 72 |
30413194 | Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer. | 2018 Nov 9 |
3 |
| 73 |
27435393 | Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder. | 2017 Jan 15 |
3 |
| 74 |
27697601 | Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. | 2017 Jan 1 |
1 |
| 75 |
28011380 | Propofol enhances the cisplatin-induced apoptosis on cervical cancer cells via EGFR/JAK2/STAT3 pathway. | 2017 Feb |
4 |
| 76 |
28275299 | Dysregulation of mRNA profile in cisplatin-resistant gastric cancer cell line SGC7901. | 2017 Feb 21 |
1 |
| 77 |
28340378 | Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. | 2017 Jun |
1 |
| 78 |
28522592 | Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib. | 2017 Aug |
2 |
| 79 |
28635183 | Cetuximab-conjugated nanodiamonds drug delivery system for enhanced targeting therapy and 3D Raman imaging. | 2017 Dec |
3 |
| 80 |
28828595 | The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro. | 2017 Dec |
6 |
| 81 |
28910149 | Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. | 2017 Sep |
1 |
| 82 |
29100507 | Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. | 2017 Nov 3 |
1 |
| 83 |
26620316 | Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299. | 2016 Mar |
1 |
| 84 |
26654941 | EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment. | 2016 Jan 19 |
2 |
| 85 |
26782932 | Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin. | 2016 Mar |
1 |
| 86 |
26895469 | A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation. | 2016 May 31 |
1 |
| 87 |
26950292 | Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer. | 2016 Jun |
1 |
| 88 |
26980454 | Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models. | 2016 Apr |
2 |
| 89 |
27029054 | Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy. | 2016 Apr 26 |
1 |
| 90 |
27073199 | Long-Term Renal Outcomes after Cisplatin Treatment. | 2016 Jul 7 |
2 |
| 91 |
27186285 | Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer. | 2016 |
6 |
| 92 |
27301192 | Aptamer Functionalized Cisplatin-Albumin Nanoparticles for Targeted Delivery to Epidermal Growth Factor Receptor Positive Cervical Cancer. | 2016 Apr |
4 |
| 93 |
27313893 | Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway. | 2016 |
2 |
| 94 |
27535835 | Silencing of fused toes homolog enhances cisplatin sensitivity in cervical cancer cells by inhibiting epidermal growth factor receptor-mediated repair of DNA damage. | 2016 Oct |
8 |
| 95 |
27602148 | Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. | 2016 Sep |
2 |
| 96 |
27614872 | Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE). | 2016 |
1 |
| 97 |
27669890 | Epidermal growth factor (EGF) receptor-ligand based molecular staging predicts prognosis in head and neck squamous cell carcinoma partly due to deregulated EGF- induced amphiregulin expression. | 2016 Sep 26 |
1 |
| 98 |
27733374 | Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer. | 2016 Dec |
2 |
| 99 |
27766772 | Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation. | 2016 Sep |
2 |
| 100 |
27884140 | Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. | 2016 Nov 25 |
1 |